Tumor Biology

, Volume 36, Issue 11, pp 9039–9047 | Cite as

HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer

  • Yirong Xu
  • Zhenwen Chen
  • Guangheng Zhang
  • Yanfeng Xi
  • Ruifang Sun
  • Fei Chai
  • Xiaogang Wang
  • Jianhong Guo
  • Lin Tian
Research Article

Abstract

High mobility group box 1 (HMGB1) is associated with tumor progression and a poor prognosis; microtubule-associated protein 1 light chain 3 (LC3) plays a critical role in autophagy. However, the roles of HMGB1 and LC3 in squamous cervical cancer (SCC) remain unclear. An array of 166 early-stage SCC, 62 cervical intraepithelial neoplasia (CIN), and 50 normal cervical tissue samples was assessed. HMGB1 and LC3 protein levels were examined by immunohistochemistry, and the associations of HMGB1 and LC3 levels with clinicopathological characteristics evaluated, to assess their prognosis significance. High nuclear HMGB1 levels were detected in 72.9 % SCC cases; 16 % cases showed cytoplasmic expression of HMGB1 in cancer cells with low nuclear expression. Interestingly, HMGB1 levels in SCC samples were significantly higher than CIN and control specimens, while lower LC3 expression was found in SCC samples (P < 0.001). Nuclear HMGB1 expression was weakly negatively correlated to LC3 amounts (r = −0.254, P = 0.001). High nuclear HMGB1 levels were associated with vascular metastasis (P < 0.05). In addition, cytoplasmic HMGB1 expression was associated with lymph node metastasis (P < 0.05). Furthermore, high nuclear HMGB1 levels and cytoplasmic HMGB1 expression predicted poor overall survival (OS) and disease-free survival (DFS). Meanwhile, high LC3 expression was associated with favorable prognosis. Multivariate analysis showed that both nuclear and cytoplasmic HMGB1 expressions were independent prognostic factors for overall- and disease-free survival, along with nodule metastasis. HMGB1 overexpression plays a significant role in SCC progression. Both nuclear and cytoplasmic HMGB1 are independent factors for poor prognosis in early-stage SCC.

Keywords

Cervical cancer Prognosis High mobility group box 1 (HMGB1) Microtubule-associated protein 1 light chain 3 (LC3) 

Notes

Acknowledgments

This work was supported by the Natural Science Foundation (2012011038–4) from Shanxi Science & Technology Department and by the Intramural Research Program of Fenyang College of Shanxi Medical University.

Conflicts of interest

None.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011;61:69–90.CrossRefGoogle Scholar
  2. 2.
    Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in china: synthesis of the evidence. Int J Cancer. 2012;130:641–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796–802.CrossRefPubMedGoogle Scholar
  4. 4.
    Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97:72–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Zur HH. Papillomavirus infections—a major cause of human cancers. Biochem Biophys Acta. 1996;1288:55–78.Google Scholar
  6. 6.
    Goldman RD, Pollack R, Hopkins NH. Preservation of normal behavior by enucleated cells in culture. Proc Natl Acad Sci U S A. 1973;70:750–4.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Goodwin GH, Johns EW. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol. 1977;16:257–67.CrossRefPubMedGoogle Scholar
  8. 8.
    Kang R, Zhang Q, Zeh HJ, Lotze MT, Tang D. Hmgb1 in cancer: good, bad, or both? Clin Cancer Res. 2013;19:4046–57.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, et al. P53/hmgb1 complexes regulate autophagy and apoptosis. Cancer Res. 2012;72:1996–2005.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ulloa L, Messmer D. High-mobility group box 1 (hmgb1) protein: friend and foe. Cytokine Growth Factor Rev. 2006;17:189–201.CrossRefPubMedGoogle Scholar
  11. 11.
    Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005;120:237–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Wiersma VR, Michalak M, Abdullah TM, Bremer E, Eggleton P. Mechanisms of translocation of er chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity. Front Oncol. 2015;5:7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhang L, Han J, Wu H, Liang X, Zhang J, Li J, et al. The association of hmgb1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review. PLoS One. 2014;9, e110626.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhao CB, Bao JM, Lu YJ, Zhao T, Zhou XH, Zheng DY, et al. Co-expression of rage and hmgb1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res. 2014;4:369–77.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Song B, Song WG, Li ZJ, Xu ZF, Wang XW, Wang CX, et al. Effect of hmgb1 silencing on cell proliferation, invasion and apoptosis of mgc-803 gastric cancer cells. Cell Biochem Funct. 2012;30:11–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee H, Song M, Shin N, Shin CH, Min BS, Kim HS, et al. Diagnostic significance of serum hmgb1 in colorectal carcinomas. PLoS One. 2012;7, e34318.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, et al. Increased expression of hmgb1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106:57–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (hmgb1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol. 2008;216:167–75.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhan Z, Li Q, Wu P, Ye Y, Tseng HY, Zhang L, et al. Autophagy-mediated hmgb1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of mcl-1. Autophagy. 2012;8:109–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhao M, Yang M, Yang L, Yu Y, Xie M, Zhu S, et al. Hmgb1 regulates autophagy through increasing transcriptional activities of JNK and ERK in human myeloid leukemia cells. BMB Rep. 2011;44:601–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia-Zepeda SP, Garcia-Villa E, Diaz-Chavez J, Hernandez-Pando R, Gariglio P. Resveratrol induces cell death in cervical cancer cells through apoptosis and autophagy. Eur J Cancer Prev. 2013;22:577–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Yang L, Yu Y, Kang R, Yang M, Xie M, Wang Z, et al. Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leuk Lymphoma. 2012;53:315–22.CrossRefPubMedGoogle Scholar
  23. 23.
    Hu X, Zhang K, Xu C, Chen Z, Jiang H. Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion. Exp Ther Med. 2014;8:229–32.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Odicino F, Pecorelli S, Zigliani L, Zigliani L, Creasman WT, Creasman WT. History of the FIGO cancer staging system. Int J Gynaecol Obstet. 2008;101:205–10.CrossRefPubMedGoogle Scholar
  25. 25.
    Basen-Engquist K, Paskett E, Buzaglo J, Miller SM, Schover L, Wenzel LB, et al. Cervical cancer. Cancer. 2003;98:2009–14.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen Z, Wang J, Zhang H, Liu D, Li Y, Xu Y, et al. Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma. Eur J Clin Invest. 2012;42:310–20.CrossRefPubMedGoogle Scholar
  27. 27.
    Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10:8465–71.CrossRefPubMedGoogle Scholar
  28. 28.
    Cheng HY, Zhang YN, Wu QL, Sun XM, Sun JR, Huang X. Expression of beclin 1, an autophagy-related protein, in human cervical carcinoma and its clinical significance. Eur J Gynaecol Oncol. 2012;33:15–20.PubMedGoogle Scholar
  29. 29.
    Charoensup J, Sermswan RW, Paeyao A, Promakhejohn S, Punasee S, Chularari C, et al. High HMGB1 level is associated with poor outcome of septicemic melioidosis. Int J Infect Dis. 2014;28:111–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013;93:865–73.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis. 2009;14:376–91.CrossRefPubMedGoogle Scholar
  32. 32.
    Tang D, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799:131–40.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood. 2006;108:2339–48.CrossRefPubMedGoogle Scholar
  34. 34.
    Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin. 2007;28:1957–67.CrossRefPubMedGoogle Scholar
  35. 35.
    Shen X, Hong L, Sun H, Shi M, Song Y. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep. 2009;22:535–9.PubMedGoogle Scholar
  36. 36.
    Jiang W, Wang Z, Li X, Fan X, Duan Y. High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res. 2012;18:293–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190:881–92.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al. Hmgb1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010;29:5299–310.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Peralta-Zaragoza O, Bermudez-Morales VH, Perez-Plasencia C, Salazar-Leon J, Gomez-Ceron C, Madrid-Marina V. Targeted treatments for cervical cancer: a review. Onco Targets Ther. 2012;5:315–28.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Yang YP, Liang ZQ, Gu ZL, Qin ZH. Molecular mechanism and regulation of autophagy. Acta Pharmacol Sin. 2005;26:1421–34.CrossRefPubMedGoogle Scholar
  41. 41.
    Bao G, Qiao Q, Zhao H, He X. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol. 2010;8:52.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Chuangui C, Peng T, Zhentao Y. The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res. 2012;18:1021–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Sasahira T, Kirita T, Oue N, Bhawal UK, Bhawal UK, Yamamoto K, et al. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci. 2008;99:1806–12.PubMedGoogle Scholar
  44. 44.
    Wang J, Pan XL, Ding L, Liu DY, Da PL, Jin T. Aberrant expression of beclin-1 and lc3 correlates with poor prognosis of human hypopharyngeal squamous cell carcinoma. PLoS One. 2013;8, e69083.CrossRefGoogle Scholar
  45. 45.
    Shen Y, Li DD, Wang LL, Deng R, Zhu XF. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy. 2008;4:1067–8.CrossRefPubMedGoogle Scholar
  46. 46.
    He JH, Luo RZ, Cai MY, Cai MF, Li M, Lu JB, et al. Decreased expression of light chain 3 (lc3) increased the risk of distant metastasis in triple-negative breast cancer. Med Oncol. 2013;30:468.CrossRefPubMedGoogle Scholar
  47. 47.
    Vernon PJ, Tang D. Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling. Antioxid Redox Signal. 2013;18:677–91.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Huebener P, Gwak GY, Pradere JP, Quinzii CM, Friedman R, Lin CS, et al. High-mobility group box 1 is dispensable for autophagy, mitochondrial quality control, and organ function in vivo. Cell Metab. 2014;19:539–47.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Zhu W, Pan X, Li F, Zhang Y, Lu X. Expression of beclin 1 and lc3 in figo stage i-ii cervical squamous cell carcinoma and relationship to survival. Tumour Biol. 2012;33:1653–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of PathologyShanxi Medical University FenYang CollegeFenyangChina
  2. 2.Department of PathologyShanxi Tumor Hospital (Shanxi Institute of Oncology)TaiyuanChina
  3. 3.Department of PathologyShanxi Fenyang HospitalFenyangChina

Personalised recommendations